Castle Biosciences Closes First Tranche of $20M Series F
July 28, 2015
Molecular diagnostics company Castle Biosciences has closed the first tranche of a $20 million Series F financing, raising $11.7 million led by Industry Ventures. The funding will be used to accelerate clinical adoption of the company's gene test for identifying metastatic risk in early stage cutaneous melanoma, DecisionDX-Melanoma, and other tests designed to improve cancer care. Castle Biosciences anticipates completing the Series F round by the end of 3Q.